Characterization of CD34-deficient myofibroblastomas of the breast.

D'Alfonso, Timothy M; Subramaniyam, Shivakumar; Ginter, Paula S; Mosquera, Juan Miguel; Croyle, Jaclyn; Liu, Yi-Fang; Rubin, Mark Andrew; Shin, Sandra J (2018). Characterization of CD34-deficient myofibroblastomas of the breast. The breast journal, 24(1), pp. 55-61. Wiley 10.1111/tbj.12835

[img] Text
D'Alfonso_et_al-2018-The_Breast_Journal.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

Mammary myofibroblastoma is a benign spindle cell tumor that can show variable morphologic patterns and lines of differentiation. Diffuse and strong immunohistochemical expression of CD34 is a characteristic of myofibroblastoma and greatly aids in confirming a diagnosis. Myofibroblastoma has been shown to belong to a family of CD34-positive tumors with similar morphology that show a deletion of 13q14, which includes RB1 and FOXO1A genes. The purpose of this study was to better understand a subset of myofibroblastomas that is characteristically CD34-deficient by immunohistochemistry. Six myofibroblastomas were studied by immunohistochemistry and fluorescence in situ hybridization (FISH) for RB1. Patients included five women and one man, aged 41-85 years (median, 52.5). Tumor size ranged from 0.4 to 1.5 cm (mean, 0.95). Tumors showed spindle cell morphology in five cases and epithelioid features in one case. Two tumors showed complete lack of CD34 staining. The remaining showed weak focal or weak patchy CD34 staining. Dichotomous staining was seen in one case with CD34-positive spindle cell areas and CD34-negative myxoid areas. All six tumors showed ER expression, five of six showed desmin expression, and four of six showed bcl-2 positivity. Two of six (33.3%) tumors showed deletion of RB1 by FISH, including one that showed loss of Rb immunohistochemical staining. Myofibroblastomas uncommonly show absent/focal expression of CD34, a potential diagnostic pitfall, particularly in small samples. Characteristic staining with other immunohistochemical markers is seen which can aid in confirming the diagnosis. These tumors may harbor deletion of RB1, similar to CD34-positive myofibroblastomas, and this deletion may not correlate with loss of Rb by immunohistochemistry.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Präzisionsonkologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Präzisionsonkologie

UniBE Contributor:

Rubin, Mark Andrew

Subjects:

500 Science
500 Science > 570 Life sciences; biology

ISSN:

1075-122X

Publisher:

Wiley

Language:

English

Submitter:

Marla Rittiner

Date Deposited:

12 Feb 2018 08:54

Last Modified:

12 Feb 2018 08:54

Publisher DOI:

10.1111/tbj.12835

PubMed ID:

28557150

Uncontrolled Keywords:

13q14 CD34 RB1 myofibroblastoma

BORIS DOI:

10.7892/boris.110726

URI:

https://boris.unibe.ch/id/eprint/110726

Actions (login required)

Edit item Edit item
Provide Feedback